Trial · NCT07912398
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS assessed by BIRC (according to Response Assessment in Neuro-Oncology [RANO] 2.0 criteria) | Up to approximately 30 months | PFS(progression-free survival ):The time from the date of randomization to the date of first disease progression (PD) confirmed by BIRC(Blinded Independent Review Committee) or death from any cause |
| Secondary | TTNI | Up to approximately 36 months | TTNI(time to next intervention ):The time from the date of randomization to the date of first initiation of any subsequent anti-tumor therapy or all-cause death |
| Secondary | TGR | every 6months,up to approximately 30 months | TGR( tumor growth rate) :The time from the date of randomization to the date of first disease progression (PD) confirmed by BIRC or death from any cause |
| Secondary | TEAEs | Up to approximately 30 months | Treatment-emergent adverse events (TEAEs) are defined as all adverse medical events that occur after participants receive the investigational medicinal product, which may manifest as symptoms, signs, diseases, or laboratory abnormalities, but are not necessarily causally related to the investigational medicinal product. |
| Secondary | PFS assessed by Investigator | Up to approximately 30 months | PFS ( progression-free survival) : the time from the date of randomization to the date of first PD confirmed by investigators or all-cause death |
| Secondary | ORR | Up to approximately 30 months | ORR(objective response rate),defined as the proportion of participants with best overall response of complete response (CR), partial response (PR), and minor response (MR) |
| Secondary | DCR | Up to approximately 30 months | DCR(disease control rate), defined as the proportion of participants with best overall response of CR(complete response), PR(partial response), MR(minor response), and SD(Stable Disease ) |
| Secondary | TTR | Up to approximately 30 months | TTR(the time to response), defined as the time from the date of randomization to the date of first documented CR(complete response), PR(partial response), MR(minor response) |
| Secondary | DoR | Up to approximately 30 months | DoR( duration of response), defined as the time from the date of first documented CR(complete response), PR(partial response), MR(minor response) to the date of first documented PD(Disease Progression) or death |
| Secondary | (CR+PR) Rate | Up to approximately 30 months | CR+PR rate(the proportion of complete response and partial response), defined as the proportion of participants with best overall response of CR(complete response), and PR(partial response) |
| Secondary | Time to CR+PR | Up to approximately 30 months | Time to CR+PR, defined as the time from the date of randomization to the date of first documented CR(complete response), or PR(partial response) |
| Secondary | Duration of CR+PR | Up to approximately 30 months | Duration of CR+PR, defined as the time from the date of first documented CR or PR to the date of first documented PD or death from any cause, whichever occurs first |
| Secondary | OS | Up to approximately 30 months | Overall survival (OS) :the time from the date of randomization to the date of all-cause death |
| Secondary | HRQoL (health-related quality of life)assessed by the FACT-Br (Functional Assessment of Cancer Therapy-Brain)questionnaire | Up to approximately 30 months | The health-related quality of life (HRQoL) will be evaluated using the Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire in participants treated with HMPL-306 versus placebo |
| Secondary | PK characteristics(plasma drug concentrations at each sampling time point) | Up to approximately 6 months | Plasma drug concentrations at each sampling time point |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07912398/registered